KMG Fiduciary Partners LLC Increases Stake in Pfizer Inc. $PFE

KMG Fiduciary Partners LLC lifted its position in shares of Pfizer Inc. (NYSE:PFE) by 26.4% during the second quarter, according to its most recent 13F filing with the Securities and Exchange Commission (SEC). The firm owned 190,888 shares of the biopharmaceutical company’s stock after purchasing an additional 39,875 shares during the quarter. KMG Fiduciary Partners LLC’s holdings in Pfizer were worth $4,597,000 as of its most recent SEC filing.

Other institutional investors have also recently made changes to their positions in the company. Brighton Jones LLC grew its position in Pfizer by 1,282.4% during the fourth quarter. Brighton Jones LLC now owns 666,318 shares of the biopharmaceutical company’s stock valued at $17,677,000 after buying an additional 618,117 shares during the period. Revolve Wealth Partners LLC raised its position in shares of Pfizer by 12.5% in the fourth quarter. Revolve Wealth Partners LLC now owns 18,766 shares of the biopharmaceutical company’s stock worth $498,000 after acquiring an additional 2,087 shares during the period. United Bank boosted its stake in shares of Pfizer by 12.4% during the 2nd quarter. United Bank now owns 58,087 shares of the biopharmaceutical company’s stock worth $1,408,000 after acquiring an additional 6,415 shares in the last quarter. Sei Investments Co. grew its position in shares of Pfizer by 31.5% during the 2nd quarter. Sei Investments Co. now owns 2,635,691 shares of the biopharmaceutical company’s stock valued at $63,889,000 after acquiring an additional 631,523 shares during the period. Finally, HUB Investment Partners LLC grew its position in shares of Pfizer by 45.3% during the 2nd quarter. HUB Investment Partners LLC now owns 102,327 shares of the biopharmaceutical company’s stock valued at $2,480,000 after acquiring an additional 31,896 shares during the period. 68.36% of the stock is owned by hedge funds and other institutional investors.

Analyst Upgrades and Downgrades

A number of equities analysts recently weighed in on the company. JPMorgan Chase & Co. reduced their price target on Pfizer from $30.00 to $28.00 and set a “neutral” rating for the company in a report on Wednesday, July 8th. Wolfe Research restated an “underperform” rating and issued a $26.00 price objective on shares of Pfizer in a research report on Thursday, May 14th. Wall Street Zen upgraded Pfizer from a “hold” rating to a “buy” rating in a research report on Saturday, August 1st. HSBC cut shares of Pfizer from a “buy” rating to a “hold” rating and dropped their price target for the company from $32.00 to $28.00 in a research note on Monday, July 6th. Finally, Guggenheim reduced their price objective on shares of Pfizer from $35.00 to $31.00 and set a “buy” rating for the company in a research report on Friday. One equities research analyst has rated the stock with a Strong Buy rating, four have given a Buy rating, fourteen have assigned a Hold rating and two have given a Sell rating to the stock. Based on data from MarketBeat.com, the company currently has an average rating of “Hold” and an average price target of $28.28.

Pfizer Price Performance

Pfizer stock opened at $27.04 on Tuesday. The company has a fifty day simple moving average of $25.05 and a 200-day simple moving average of $26.18. The firm has a market capitalization of $154.12 billion, a price-to-earnings ratio of 35.58 and a beta of 0.34. The company has a quick ratio of 0.96, a current ratio of 1.27 and a debt-to-equity ratio of 0.71. Pfizer Inc. has a 52-week low of $23.58 and a 52-week high of $28.75.

Pfizer (NYSE:PFE) last announced its quarterly earnings data on Tuesday, August 4th. The biopharmaceutical company reported $0.77 earnings per share (EPS) for the quarter, beating the consensus estimate of $0.68 by $0.09. Pfizer had a net margin of 6.80% and a return on equity of 19.63%. The company had revenue of $15.03 billion during the quarter, compared to analysts’ expectations of $14.40 billion. During the same quarter in the prior year, the company earned $0.78 EPS. Pfizer’s revenue was up 2.6% compared to the same quarter last year. Pfizer has set its FY 2026 guidance at 2.800-3.000 EPS. On average, equities analysts anticipate that Pfizer Inc. will post 2.97 EPS for the current fiscal year.

Pfizer Dividend Announcement

The business also recently declared a quarterly dividend, which will be paid on Tuesday, September 1st. Investors of record on Friday, July 24th will be issued a $0.43 dividend. This represents a $1.72 annualized dividend and a dividend yield of 6.4%. The ex-dividend date of this dividend is Friday, July 24th. Pfizer’s dividend payout ratio (DPR) is currently 226.32%.

Pfizer Profile

Pfizer Inc (NYSE: PFE) is a multinational biopharmaceutical company headquartered in New York City. Founded in 1849 by Charles Pfizer and Charles Erhart, the company researches, develops, manufactures and commercializes a broad range of medicines and vaccines for human health. Its activities span discovery research, clinical development, regulatory affairs, manufacturing and global commercial distribution across multiple therapeutic areas.

Pfizer’s portfolio and pipeline cover oncology, immunology, cardiology, endocrinology, rare diseases, hospital acute care and anti-infectives, along with a substantial vaccine business.